Omega Diagnostics Group Plc (LON:ODX)‘s stock had its “corporate” rating reissued by investment analysts at FinnCap in a research note issued to investors on Tuesday. They presently have a GBX 28 ($0.35) target price on the stock. FinnCap’s price objective would indicate a potential upside of 53.42% from the company’s current price.

Shares of Omega Diagnostics Group Plc (LON:ODX) opened at 18.0625 on Tuesday. The stock’s market cap is GBX 19.64 million. Omega Diagnostics Group Plc has a 52-week low of GBX 13.50 and a 52-week high of GBX 21.00. The firm’s 50-day moving average is GBX 17.37 and its 200 day moving average is GBX 17.23.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this report can be read at

About Omega Diagnostics Group Plc

Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers.

Receive News & Ratings for Omega Diagnostics Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group Plc and related companies with's FREE daily email newsletter.